TFF Pharmaceuticals and the National Institute of Environmental Health Sciences (NIEHS) have signed an agreement for the development of dry powder formulations of high molecular weight hyaluronan (HMW-HA) for respiratory diseases.

Under the collaborative research and development agreement (CRADA), respirable dry powder formulations of HMW-HA will be developed for prevention and treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This follows earlier research which demonstrated that HMW-HA yielded dry powder formulations with desirable aerosol performance when formulated with thin film freezing technology.

TFF Pharmaceuticals and NIEHS will investigate the TFF-HMW-HA formulations’ therapeutic efficacy and pharmacokinetics using in vitro and in vivo models of respiratory diseases.

Their primary focus will be on chronic obstructive pulmonary disorder as well as viral respiratory diseases caused by SARS-CoV-2, the influenza virus and/or respiratory syncytial virus (RSV).

TFF Pharmaceuticals stated that other indications including acute and chronic lung allograft rejection, asthma, halogen-induced acute lung injury and cystic fibrosis may also be explored.

TFF Pharmaceuticals CEO Harlan Weisman said: “Thin film freezing is a technology that possesses several advantages in engineering particles for various routes of administration, including for delivering the drug to the lungs, which could hold significant potential for the treatment of numerous respiratory diseases.

“Since 2020, TFF Pharmaceuticals has entered into multiple CRADAs with various US government agencies that cover a broad range of applications, and today’s announcement with NIEHS is further recognition of thin film freezing’s potential.”

The company stated that its TFF technology facilitates the transformation of existing compounds as well as new chemical entities into dry powder formulations, showing characteristics and benefits that are unique.

Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.